DVAX David F Novack sells $190K worth of shares
Mar 21, 2025, 4:31 AM
0.00%
What does DVAX do
Dynavax Technologies is a biopharmaceutical company based in Emeryville, California, specializing in vaccines and immuno-oncology therapeutics, including the HEPLISAV-B hepatitis B vaccine. The company is developing additional vaccines, including candidates for shingles and Tdap.
David F Novack sold 14,020 shares of DVAX on 18 March at $13.58 per share, worth a total of $190K. They now own 8,078 DVAX shares, or a 63% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.